ES2357296T3 - Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer. - Google Patents

Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer. Download PDF

Info

Publication number
ES2357296T3
ES2357296T3 ES00955686T ES00955686T ES2357296T3 ES 2357296 T3 ES2357296 T3 ES 2357296T3 ES 00955686 T ES00955686 T ES 00955686T ES 00955686 T ES00955686 T ES 00955686T ES 2357296 T3 ES2357296 T3 ES 2357296T3
Authority
ES
Spain
Prior art keywords
epha2
cells
metastatic
antibody
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00955686T
Other languages
English (en)
Spanish (es)
Inventor
Michael Scott Kinch
Nicole Dodge Zantek
Katherine E Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2357296T3 publication Critical patent/ES2357296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES00955686T 1999-08-17 2000-08-17 Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer. Expired - Lifetime ES2357296T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
US149259P 1999-08-17

Publications (1)

Publication Number Publication Date
ES2357296T3 true ES2357296T3 (es) 2011-04-25

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00955686T Expired - Lifetime ES2357296T3 (es) 1999-08-17 2000-08-17 Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer.

Country Status (8)

Country Link
EP (2) EP2312316A1 (enExample)
JP (3) JP4948728B2 (enExample)
AT (1) ATE483978T1 (enExample)
AU (1) AU785445C (enExample)
CA (1) CA2382655A1 (enExample)
DE (1) DE60045075D1 (enExample)
ES (1) ES2357296T3 (enExample)
WO (1) WO2001012840A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1453530A2 (en) * 2001-11-09 2004-09-08 Neuronova AB Method of proliferation in neurogenic regions
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
CA2542631A1 (en) * 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
ATE483978T1 (de) 2010-10-15
EP2312316A1 (en) 2011-04-20
EP1210603A2 (en) 2002-06-05
JP2007291140A (ja) 2007-11-08
AU785445C (en) 2008-01-31
WO2001012840B1 (en) 2001-09-27
AU785445B2 (en) 2007-06-14
AU6784300A (en) 2001-03-13
JP2003507023A (ja) 2003-02-25
JP4948728B2 (ja) 2012-06-06
DE60045075D1 (de) 2010-11-18
WO2001012840A3 (en) 2001-05-03
CA2382655A1 (en) 2001-02-22
JP2012103264A (ja) 2012-05-31
EP1210603B1 (en) 2010-10-06
WO2001012840A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
ES2357296T3 (es) Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer.
US20070161064A1 (en) Antibodies as a cancer diagnostic
US7910316B2 (en) Kit and method for detecting urothelial cancer
WO2008028066A2 (en) Boris isoforms and methods of detecting and treating disease
EP2449133B1 (en) Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53 isoforms
US7488584B2 (en) Methods for diagnosing and treating kidney and colorectal cancer
TW201018912A (en) Methods and kits for the detection of metastasis cancers
EP3144676B1 (en) Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer
US20060121540A1 (en) Use of protein MASP as a marker for colorectal cancer
AU2011253563A1 (en) Anti-epha2 antibodies as a cancer diagnostic
AU2007202091A1 (en) Anti-epha2 antibodies as a cancer diagnostic
US20130203059A1 (en) Method for Diagnosis of Bladder Cancer and Related Kits
EP1654538B1 (en) Use of protein proteasome activator subunit 3 (pse3) as a marker for colorectal cancer
US20130095483A1 (en) Predictive biomarkers for breast cancer
US20120276539A1 (en) Use of metastasis progressor s100a4 transcripts in body fluids of colorectal and gastric cancer patients
WO2020229717A1 (es) Método para predecir la respuesta terapéutica a fármacos inhibidores de la serina-treonina kinasa braf
Class et al. Patent application title: Method for Diagnosis of Bladder Cancer and Related Kits Inventors: Antonio Feliciello (Parete, IT) Luigi Insabato (Napoli, IT) Assignees: Topogen, Inc.
WO2005015234A1 (en) Use of protein sahh as a marker for colorectal cancer